Click here for our latest news and resources on COVID-19

News & Events


  • Obtain COVID-19-related Patents Fast . . . At No Additional Cost!

    By Procopio Partners Stephen C. Beuerle and Robert “Bob” Ramos In the agency’s latest action related to the coronavirus pandemic, the United States Patent and Trademark Office (USPTO) May 8 announced a new, free Prioritized Examination Pilot Program for products or processes that are subject to U.S. Food and Drug Administration (FDA) approval for use in the prevention and/or treatment of COVID-19. The USPTO will grant requests for prioritized examination to patent applicants tha...

    Read More
  • USPTO Further Extends Certain Patent Filing Deadlines

    By Procopio Partner Bob Ramos The Director of the U.S. Patent and Trademark Office (USPTO) indicated that because “[i]nnovation and entrepreneurship will play a key role in our fight against this pandemic, and in the upcoming recovery of our country…the USPTO continues to assess measures to support the work of inventors and entrepreneurs during this crisis and beyond.” Accordingly, the Director has further extended several patent-related deadlines that would have been, or would be, ...

    Read More
  • USPTO Extends Certain Patent Filing Deadlines

    By Procopio Partner Robert “Bob” Ramos The U.S. Patent and Trademark Office (USPTO) recently exercised its authority granted by the CARES Act stimulus package to extend several patent-related deadlines that would have been due on or after March 27, 2020, through April 30, 2020. The specific deadlines that can be extended include: Responses to Official Actions, Issue Fee Payments, Maintenance Fee Payments, Notice of Appeals, Appeal Briefs, Reply Briefs, and Requests for oral hearings b...

    Read More
  • CARES Act Provides USPTO Discretion to Extend Certain Patent and Trademark Filing Deadlines

    By Procopio Partner Robert (Bob) Ramos The Coronavirus Aid, Relief, and Economic Security (CARES) Act signed into law by the President on March 27, 2020, contains language aimed at addressing concerns within the intellectual property community. In addition to both individual and corporate financial relief, Section 12004 of the CARES Act also gives the U.S. Patent and Trademark Office (USPTO) Director the discretion, during the COVID-19 emergency, to “toll, waive, adjust, or modify, any ...

    Read More
  • Millennium Case May Strengthen IP Portfolios of Pharma Companies

    In a precedential decision that may bolster certain patent claims in the life sciences, the U.S. Court of Appeals for the Federal Circuit on July 17, 2017, held in Millennium Pharmaceuticals, Inc. v. Sandoz Inc. that the lyophilized D-mannitol ester of  bortezomib, --the active ingredient in Velcade®—was non-obvious. Sandoz and other pharmaceutical companies sought to create generic versions of Velcade®, arguing that some of the patent claims held by Millennium were invalid becau...

    Read More